Anti-obesity drugsinclude all pharmacological treatments intended to reduce or control weight. Because these drugs are intended to alter one of the fundamental processes of the human body, anti-obesity drugs are medically prescribed only in cases of morbid obesity, where weight loss is life-saving.
Mechanisms of action
Anti-obesity drugs operate through one or more of the following mechanisms:
- Suppression of the appetite.
- Increase of the body’s metabolism.
- Interference with the body’s ability to absorb specific nutrients in food. For example, orlistat blocks fat breakdown and thereby prevents fat absorption.
Anorectics (also known as anorexigenics) are primarily intended to suppress the appetite, but most of the drugs in this class also act as stimulants (dexedrine, e.g.), and patients have abused drugs “off label” to suppress appetite (e.g. digoxin).
Some anti-obesity drugs have severe and often life-threatening side effects. (See, for example, Fen-phen.) These side effects are often associated with their mechanism of action. In general, stimulants carry a risk of high blood pressure, faster heart rate, palpitations, closed-angle glaucoma, drug addiction, restlessness, agitation, and insomnia.
Another drug, Orlistat, blocks absorption of dietary fats, and as a result may cause oily spotting bowel movements, oily stools, stomach pain, and flatulence.
Limitations of current knowledge
The limitation of drugs for obesity is that we still do not know fully the neural basis of appetite and how to modulate it. Appetite is clearly a very important instinct to promote survival. Arguably any drug that would abolish appetite may carry a high mortality risk and may be unsuitable for clinical use.
Because the human body uses various chemicals and hormones to protect its stores of fat (a reaction probably useful to our ancestors when food was scarce in the past,) there has not yet been found a ‘silver bullet’, or a way to completely circumvent this natural habit of protecting excess food stores. Because of this, anti-obesity drugs are not a practical long-term solution for people who are overweight.
More recent developments may be promising in development of drugs that can combat obesity. The discovery of cannabinoid receptors in the brain, liver and muscle has stimulated research in a new class of drugs, namely cannabinoid (CB1) receptor antagonists. One such drug in development is Rimonabant from Sanofi-Aventis, it is designed to block the effects of endogenous cannabinoids. This type of drug is particularly interesting since it not only causes weight loss but reverses the metabolic effects of obesity such as insulin resistance and hyperlipidemia. It is also interesting to note that this class of drugs may decrease the tendency to abuse substances such as alcohol and tobacco. The weight loss reported with rimonabant is modest (approximately 20 lbs.), although it is unlikely that this drug will successfully treat morbid obesity. It promises to be very useful in treating modest obesity and reversing some of the metabolic complications of this condition.
- Snow V, Barry P, Fitterman N, Qaseem A, Weiss K; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005;142:525-31. Fulltext. PMID 15809464.
- Prescription Medications for the Treatment of Obesity
- General review of diet pills
- Diet pills & supplements Open directory resource for diet supplements